All In MedTech

Device Trial Radar · NCT07008001

Assessment of DOT Spectacles in Chinese Children Extension

Clinical Assessment of DOT Spectacle Lenses in Chinese Children Extension

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 175 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

175

Planned (sponsor's estimate)

Start

Aug 1, 2025

Primary completion

Dec 31, 2026

Study completion Jun 30, 2027

Sponsor

Lead sponsor
SightGlass Vision, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jun 6, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 8 years, up to 16 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, controlled, open-label, evaluator-blinded, multicenter, clinical trial of 12-months duration to evaluate the continued safety and efficacy of Diffusion Optics Technology (DOT) spectacle lenses in reducing the progression of juvenile myopia in children of Chinese origin.

Conditions

  • Juvenile Myopia
  • Myopia

Interventions

  • Novel spectacle lens designDevice

    Use of spectacle lenses may reduce the rate of progression of juvenile myopia

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Axial length Group ITime frame: 12 months
  2. Axial length Group IITime frame: 12 months

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Aier Eye Hospital

    Changsha, China

  • West China Hospital

    Chengdu, China

  • Zhongshan Ophthalmic Center

    Guangzhou, China

2 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.